سعر زالكوري Xalkori‏ 250مجم 60 كبسولة 2026

Xalkori 250 mg 60 caps: Crizotinib 250 mg hard capsule (Pfizer).

• Most common in NSCLC (>=25%): vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, neuropathy.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• None (per US label).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hepatotoxicity, which can be fatal: monitor liver tests; interstitial lung disease/pneumonitis; QT prolongation; bradycardia.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Severe visual loss and other vision disorders; severe gastrointestinal toxicity in pediatric patients; embryo-fetal toxicity.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A inhibitorsAvoid concomitant use; if unavoidable, reduce crizotinib dose per label.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A inducersAvoid concomitant use (reduced crizotinib exposure).DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm based on mechanism and animal data; advise effective contraception.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Crizotinib: Tyrosine kinase inhibitor of ALK, ROS1 and MET (US Xalkori label).